Summary of Fosun Pharmaceutical Conference Call Company Overview - **Company**: Fosun Pharmaceutical (复星医药) - **Industry**: Healthcare and Pharmaceuticals Key Points and Arguments 1. **Turnaround Potential**: Fosun Pharmaceutical is expected to reach a turning point with improved profitability across its business segments, particularly in innovative drugs. The company’s product pipeline is considered undervalued, and the ongoing divestiture of non-core assets is anticipated to enhance its financial condition [1][11][12]. 2. **Stock Performance**: Year-to-date, Fosun's A-shares have increased by 29%, while H-shares have risen by 86%. The disparity in performance is attributed to the narrowing of the A-H share premium from 62% at the beginning of 2025 to 34% currently. The significant rise in the stock price of its subsidiary, Henlius, which is up 274% year-to-date, reflects the market's recognition of its innovative drug pipeline [1][11][12]. 3. **Management Changes and Guidance**: The appointment of a new chairman in June 2025 and the announcement of an employee stock ownership plan for A and H shares indicate a strategic shift. The management has set a target for a 20% CAGR in net profit and a 19% CAGR in sales for innovative drugs from 2024 to 2027, suggesting potential upside compared to market expectations [1][11][12]. 4. **Valuation of New Drugs**: By 2030, new drugs are projected to drive 68% of Fosun's valuation, accounting for 45% of total pharmaceutical sales. The innovative drug pipeline, particularly from Henlius, is valued at RMB 72 billion, with significant contributions from key drugs like HLX43, HLX22, and serplulimab [2][20]. 5. **Asset Divestiture Strategy**: High leverage has been a major investment risk. Since 2024, management has reduced debt through the divestiture of non-strategic assets, generating approximately RMB 50 billion in returns. The company aims to achieve annual cash inflows of RMB 30 billion from asset sales over the next three years to improve its capital structure [3][34]. 6. **Upgraded Ratings and Price Targets**: The rating for A and H shares has been upgraded to "Overweight," with target prices set at RMB 42 and HKD 33, respectively. The expected net profit growth rate for 2025 is 20%, driven primarily by the sales ramp-up of new drugs, which is projected to have a CAGR of 18% from 2025 to 2028 [4][38]. 7. **Research and Development Focus**: Fosun's internal R&D team has strategically prioritized its pipeline, focusing on high-value projects while terminating less promising ones. The company has made significant investments in small molecules, cell and gene therapies, and vaccines, with 61-71% of R&D expenditures directed towards its internal pipeline [26][27]. 8. **Clinical Development and Market Potential**: Key drugs in development, such as HLX43 and HLX22, are showing promising clinical data, with HLX43 positioned favorably in the NSCLC market. The company is also exploring additional indications for its drugs, which could further enhance market potential [15][19][18]. 9. **Financial Metrics**: The current market capitalization is approximately RMB 75.215 billion, with an expected EPS of RMB 1.25 for 2025. The company’s PE ratios are projected at 24.0 for 2025, indicating that the stock is undervalued compared to peers [6][12]. Other Important but Overlooked Content - **Subsidiary Performance**: The performance of subsidiaries like Henlius and Gland Pharma is crucial for Fosun's valuation, with Henlius contributing significantly to new drug sales. The management anticipates improvements in profitability from these subsidiaries in the coming quarters [36][37]. - **Market Dynamics**: The healthcare sector in China is experiencing a rebound, with indices like the Hang Seng Healthcare Index showing significant gains. However, Fosun's past performance has been hindered by high debt levels and a mixed business model, which the company is actively working to address [11][12]. - **Future Catalysts**: Upcoming key data readouts and regulatory submissions for its drugs are expected to be significant catalysts for stock performance and market perception [25][36]. This comprehensive summary captures the essential insights from the conference call regarding Fosun Pharmaceutical's current status, strategic direction, and market outlook.

Core Insights - Mutual funds have shown significant activity in various segments, with notable additions and reductions across large-cap, mid-cap, and small-cap stocks. Large-Cap Segment - Key additions by mutual funds included Eternal (Rs 7,200 crore), Infosys (Rs 5,000 crore), and HDFC Bank (Rs 3,100 crore) [6] - Major reductions were observed in Maruti Suzuki (Rs 3,100 crore), Avenue Super (Rs 2,900 crore), and NTPC (Rs 2,700 crore) [6] - Consistent additions over three months included State Bank of India, Bajaj Finance, Kotak Mahindra Bank, Axis Bank, and Titan Company, while reductions were seen in Coal India, Grasim Industries, TVS Motor Co, LTIMindtree, and Solar Industries [6] Mid-Cap Segment - Significant additions included Bank Of Maharashtra, Escorts Kubota, Blue Star, Gujarat Fluorochem, and Global Health, while key reductions were in ACC, Exide Industries, KPIT Tech, Metro Brands, and Gland Pharma [4][6] - Notable buying was seen in One 97, L&T Finance, Thermax, Tata Communications, and Coforge, with selling occurring in Exide Industries, Muthoot Finance, HDFC AMC, JK Cements, and LIC Housing Finance [6] Small-Cap Segment - Important additions by mutual funds included Bluestone Jewellery (Rs 4,000 crore), Medi Assist Health (Rs 3,000 crore), and Thirumalai Chem (Rs 2,000 crore) [5] - Key reductions were in Aditya Birla Fashion (Rs 4,000 crore), JK Tyre & Industries (Rs 1,000 crore), and Senco Gold (Rs 1,000 crore) [5] - New entries in the small-cap segment included Thirumalai Chemicals, Suven Life Sciences, PSP Projects, Foseco India, and Epack Durable, while exits included Thomas Cook, Sarda Energy, Faze Three, and Hindware Home Interiors [5] Overall Trends - The total cash and equivalents held by mutual funds decreased from Rs 1.85 lakh crore (5.46%) in July to Rs 1.76 lakh crore (5.23%) in August [6] - Significant buying was noted in Clean Science, Home First Finance, Syrma SGS Tech, Krishna Institute, and KFin Technologies, while the highest selling was in Hitachi Energy, BSE, PNB Housing, and Aditya Birla Fashion [5][6]

据 IPO 早知道消息，复星国际（ 0656.HK ） 于近日发布了 2024 年全年业绩。 2024 年总收入录 得人民币 1921.4 亿元；产业运营利润 49 亿元；四大核心子公司，包括豫园股份、复星医药、复星 葡萄牙保险和复星旅文总收入达 1346.5 亿元，占集团总收入的比重达 70.1% ；总债务占总资本比 率为 52% ；现金、银行结余及定期存款为 1,063.4 亿元； 海外收入占总收入比重升至 49.3% ，同 比增长 6.2% ； 全年科创投入合计约 69 亿元。 报告期内，集团层面资产退出签约约人民币 175 亿元等值，合并报表层面资产退出签约约人民币 300 亿元等值。尽管单个项目带来的账面价值调整影响了 2024 年的财务表现，但复星的整体运营 基本面及核心产业仍然稳健。 2024 年，复星医药 作为健康板块核心企业， 实现营业收入人民币 409.1 亿元，归母净利润 27.7 亿元，同比增长 16.08% ， 其中中国大陆以外地区和其他国家收入 112.97 亿元，同比增长 8.93% ，占比 27.63% 。 经营现金流 44.77 亿元，同比增长 31.13% 。增长主要得益于 ...

复星医药在创新研发、许可合作、生产运营及商业化等多维度持续践行国际化战略，2024年，复星医药 海外收入112.97亿元，占营收比重27.51%。 报告期内，复星医药持续推进生产体系的国际质量标准认证，进一步夯实制剂出海基础。截至2024年 末，复星医药制药板块国内控股子公司所有商业化生产线均已通过国内GMP认证，并已有10条生产线 通过美国、欧盟等主流法规市场GMP认证。 【环球网报道 记者 姚倩】在经历了连续两年的净利润负增长之后，复星医药2024年净利润回归两位数 增长。3月25日，复星医药发布2024年度（报告期）业绩报告。公司实现营业收入410.67亿元，归母净 利润27.7亿元，同比增加16.08%；实现经营现金流44.77亿元，同比增长31.13%。 目前，复星医药制药与医疗器械业务已主要覆盖美国、欧洲、非洲、印度和东南亚等海外市场，海外商 业化团队超1000人。在美国，复星医药的仿制药自营团队日趋成熟，与各大分销商及集团采购组织 （GPO）均建立合作关系，推进制剂产品销售。与此同时，复星医药已组建美国创新药团队，并开展创 新药抗PD-1单抗斯鲁利单抗注射液的商业化筹备工作。 来源：环球网 在欧 ...

Core Viewpoint - Fosun Pharma has reported a slight decline in revenue for 2024, but a significant increase in net profit, indicating a mixed financial performance amidst ongoing challenges in the market [3][4]. Financial Performance - The company achieved a revenue of 41.07 billion yuan in 2024, a decrease of 0.8% compared to 2023 [4][8]. - Net profit attributable to shareholders was 2.77 billion yuan, reflecting a year-on-year growth of 16.08% [4][8]. - The net profit after excluding non-recurring items was 2.31 billion yuan, up 15.10% from the previous year [4][8]. - Operating cash flow increased by 31.13% to 4.48 billion yuan [4][8]. Revenue Breakdown - In 2024, the pharmaceutical segment generated 28.92 billion yuan, down 4.29% year-on-year [6][7]. - Medical devices and diagnostics reported revenue of 4.32 billion yuan, a decrease of 1.53% [6][7]. - Healthcare services saw a revenue increase of 14.61%, totaling 7.65 billion yuan [6][7]. - Revenue from the mainland China market was 29.77 billion yuan, down 4.06%, while international markets contributed 11.30 billion yuan, up 8.93% [6][7]. Asset and Liability Management - Total assets reached 1174.61 billion yuan, a 3.52% increase from the beginning of the year [9]. - Total liabilities amounted to 575.27 billion yuan, reflecting a 1.18% increase [9]. - The debt-to-asset ratio stood at 48.98%, a decrease of 1.13 percentage points year-on-year [9]. Shareholder and Market Response - The company announced a cash dividend of 3.2 yuan per share, with a payout ratio of 72% [9]. - The stock price fell to 24.55 yuan per share following the annual report release, resulting in a market capitalization of 65.58 billion yuan, which is over 70% lower than its peak in 2021 [10]. External Financing and Guarantees - Fosun Pharma has a high level of external guarantees, totaling 236.98 billion yuan, which is 51.87% of the net assets as of the end of 2023 [10]. - The company has been actively selling financial assets to recover funds, with approximately 3 billion yuan raised through asset sales last year [9].

Core Insights - The company aims to continue divesting non-core, non-strategic, low-efficiency, and loss-making assets by 2025 to enhance cash flow [1][2][3] - In 2024, the company reported a revenue of 41.067 billion yuan, a year-on-year decrease of 0.8%, while net profit attributable to shareholders increased by 16.1% to 2.77 billion yuan [1] - The operating cash flow for 2024 was 4.48 billion yuan, reflecting a year-on-year growth of 31.1%, surpassing the growth rate of operating profit [1] Asset Management Strategy - The company has been actively selling assets to replenish working capital and repay interest-bearing debts, including the sale of a 6.01% stake in Gland Pharma for a total consideration of 211 million USD [2] - In March 2025, the company announced the sale of 9.4 million shares of Unicorn II Holdings Limited for 124 million USD, resulting in a complete exit from the company [2] - The company has recognized the need to streamline its asset portfolio, focusing on core business areas to improve asset efficiency and structure [3] Financial Health - As of the end of 2024, the company's debt-to-asset ratio was 48.98%, a slight decrease from 50.10% at the end of 2023, indicating ongoing debt pressure [3]

Core Insights - Fosun Pharma reported a slight decline in revenue for 2024, with total revenue at 41.067 billion yuan, a decrease of 0.8% year-on-year [1][2] - The net profit attributable to shareholders increased by 16.08% to 2.77 billion yuan, while the net profit excluding non-recurring items rose by 15.1% to 2.314 billion yuan [1][2] - The company reduced its R&D personnel by 444, bringing the total to 3,047, which constitutes 7.51% of the total workforce [3][4] Financial Performance - Revenue for 2024: 41.067 billion yuan, down from 41.400 billion yuan in 2023 [2] - Net profit attributable to shareholders: 2.769 billion yuan, up from 2.386 billion yuan in 2023 [2] - Net profit excluding non-recurring items: 2.314 billion yuan, compared to 2.011 billion yuan in 2023 [2] - Cash flow from operating activities increased by 31.13% to 4.477 billion yuan [2] R&D Personnel Changes - R&D personnel count decreased from 3,491 in 2023 to 3,047 in 2024, a reduction of 444 [3][5] - R&D personnel now represent 7.51% of the total workforce, down from 8.65% in the previous year [3][5] - Educational background of R&D staff includes 242 with doctoral degrees and 1,363 with master's degrees [4] Executive Compensation - The total annual salary of the CEO, Wenjie Zhang, is 10.24 million yuan, which is higher than that of the chairman [5][7] - Other executives with salaries exceeding 5 million yuan include Xingli Wang (9.857 million yuan), Rong Yang (6.210 million yuan), and Wang Kexin (5.343 million yuan) [5]

Core Viewpoint - The report highlights the significant advancements and strategic initiatives of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in the pharmaceutical and medical device sectors, emphasizing innovation, compliance, and market expansion as key drivers for growth in 2024. Company Overview - The pharmaceutical industry is driven by innovation, with the government prioritizing the development of innovative drugs as a new emerging industry [5][6] - The company has maintained a strong position in the industry, ranking 4th in the "2023 Annual Top 100 Chinese Pharmaceutical Industry" list [12] Industry Development Status - The implementation of the "Drug Standard Management Measures" in January 2024 aims to enhance drug quality and safety [8] - Continuous anti-corruption efforts in the medical and pharmaceutical sectors are expected to promote long-term healthy development [8] - The government has introduced policies to support the upgrade of medical equipment, providing new sales opportunities for the medical device industry [9] Business Highlights - The company achieved operating revenue of 41.067 billion yuan in the reporting period, with significant growth in innovative products [26] - The net profit attributable to shareholders increased by 16.08% to 2.770 billion yuan, with a net profit excluding non-recurring gains and losses rising by 15.10% [26] - The company has focused on innovation, with R&D investment totaling 5.554 billion yuan, of which 3.644 billion yuan was dedicated to R&D expenses [27] Product Development - The company has received approvals for 16 indications across 7 innovative drugs and biosimilars during the reporting period [28] - The innovative PD-1 monoclonal antibody, Hanshu (SruLi), received approval for a new indication in China [29] - The company has successfully launched several products in international markets, including the biosimilar trastuzumab in the US and Canada [29][30] Global Expansion - The company has established a strong global presence, with a commercial team of over 1,000 people covering markets in the US, Africa, and other regions [42] - The company has formed strategic partnerships to enhance its international market access and product commercialization [38][39] Compliance and Regulatory Environment - The company is committed to adhering to regulatory requirements and enhancing compliance in response to the ongoing anti-corruption initiatives in the pharmaceutical industry [25] - The company has implemented measures to ensure the quality and safety of its products, aligning with national standards and regulations [41]